Daniel Faga

Daniel Faga has more than 20 years of business and advisory experience in life sciences industry. He currently serves as interim Chief Executive Officer and Director of AnaptysBio. Prior to AnaptysBio, Mr Faga served as Chief Operating Officer and Principal Financial Officer of Mirati Therapeutics where his responsibilities included leading the company’s corporate strategy, business development, finance, legal and other G&A related functions. Before Mirati, he was Chief Business Officer at Spark Therapeutics until its acquisition by Roche in 2019 for $4.8 billion. Previously, Mr. Faga was Managing Director at Centerview Partners and began his career in investment banking and management consulting working at Merrill Lynch and PRTM.

Mr. Faga earned an MBA in healthcare management from The Wharton School at the University of Pennsylvania and holds a BS in engineering from Cornell University.